HOME > SOCIETY > SCIENCE > US FDA updates warning against widespread use of fluoroquinolones

US FDA updates warning against widespread use of fluoroquinolones

fluoroquinolone-toxicity-protestThe US Food & Drug Administration issued a warning against casual usage of fluoroquinolone antibiotics, arguably the most widely used broad-spectrum antibiotic in India.

USFDA advised that the side effects caused by the use of fluoroquinolone antibacterial drugs would outweigh the benefits for patients who have alternative treatment options.

Patients with acute sinusitis, acute bronchitis and uncomplicated urinary tract infections who have other treatment options should look at other options, the FDA said.  Fluoroquinolones should be reserved for those who do not have alternative treatment options.

In an FDA safety review, the fluoroquinolones, when used systemically, have been found to be associated with disabling and potentially permanent serious side effects occurring together, it said.

These side effects can involve the tendons, muscles, joints, nerves, and central nervous system.

Fluoroquinolones have emerged as the drug of choice for doctors treating everything from ear infection to sinusitis to serious and life-threatening infections due to their potency.

Fluoroquinolone drugs work by disrupting the DNA replication in bacteria, thus killing off their colonies and bringing infections under control.

However, due to the extreme efficiency, they tend to ‘wipe the slate clean’ when it comes to essential and often crucial bacteria that the human body needs for its proper functioning, and can often lead to a condition known as disbiosis and ‘leaky gut syndrome’.

The oral usage of flouroquinolones allegedly leads to increased permeability of the intestinal walls, which in turn leads to the alleged leakage of food particles and toxins into the blood, and via the blood to other organs. Restitution therapies include the use of probiotics to try to restore the gut flora as far as possible.

“While these drugs are effective in treating serious bacterial infections, FDA review found that both oral and injectable fluroquinolones are associated with disabling side effects involving the tendons, muscles, joints, nerves and the central nervous system. These side effects can occur hours to weeks after exposure to fluoroquinolones and may potentially be permanent,” FDA said.

The drug already has black-box warnings for it’s side effects and other warnings related to nervous damage, muscle weakness and fatigue.

A black box warning is the strictest warning put in the labeling of prescription drugs or drug products by the Food and Drug Administration (FDA) when there is reasonable evidence of an association of a serious hazard with the drug.

The fluoroquinolones which are sold in the market are velox (Moxifloxacin), Cipro (Ciprofloxacin), Factive (Gemifloxacin), Levaquin (Levofloxacin) and generic Ofloxacin.

In India, these drugs are available in their generic forms and are marketed by most big drug companies. Though not supposed to be given to children and old people, they are prescribed to kids as young as two in India.

This is not the first time FDA is warning about this anti bacterial drug. FDA previously communicated safety information associated with systemic fluoroquinolone antibacterial drugs in August 2013 and July 2008. The safety issues described in this Drug Safety Communication were also discussed at an FDA Advisory Committee meeting in November 2015.

In July, the FDA approved labelling changes for Fluoroquinolones and urged patients to consult with their health care professional immediately on experiencing any serious side effects including tendon, joint and muscle pain, a “pins and needles” tingling or pricking sensation, confusion, and hallucinations.

Health care professionals should stop systemic fluoroquinolone treatment immediately if a patient reports serious side effects, and switch to a non-fluoroquinolone antibacterial drug to complete the patient’s treatment course, it had warned.

The adverse reactions to the drugs have led to the emergence of several online help forums as well as groups of Facebook.

Follow ULTRA.news
Lupin gets USFDA nod for scalp solution Pharma Major Lupin announced that it has received final approval from the US Food & Drug Administration to market a generic version of Dovonex Scalp Solution from Leo Pharmaceutical Products Ltd. Calcipotriene Topical Solution is indicated for the topical treatment of chroni...
Aurobindo Pharma gets USFDA nod for generic deep vein thrombosis drug Aurobindo Pharma Limited said it received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fondaparinux Sodium injection -- a bioequivalent and therapeutic equivalent to Arixtra of Mylan Ireland. The product, used to prevent deep vein th...
Lupin gets US approval for generic version of Bayer’s oral contraceptive Pharma Major Lupin said it got the approval of the US Food and Drug Administration to launch a generic version of Bayer's oral contraceptive Safyral. The branded version has annual sales of around $23 mln in the US. Lupin's product will be called Tydemy. The combination...
Glenmark reports successful trial for nasal spray, to file NDA soon Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that its nasal spray Ryaltris met safety and efficacy goals in a Phase 3 clinical study in treating perennial allergic rhinitis. With the positive results, the company said it plans to submit an applica...
DENGUE DEATH: Haryana govt probe finds Fortis Hospital guilty An official inquiry by the Haryana government has found the Gurgaon Fortis hospital guilty of overcharging and several other violations of law, media outlets reported. Quoting the official copy of the report, Mirror Now said that the inquiry committee found the hospital guilty...
Crucial win for Biocon as FDA approves cancer biosimilar trastuzumab Biocon and its partner Mylan scored a key victory on Friday as the US Food & Drug Administration approved its cancer-treating biosimilar trastuzumab. "Mylan anticipates potentially being the first company to offer a biosimilar to Herceptin, as a result of Mylan's ability to s...
Boosted by Jio’s success, Mukesh Ambani unveils his future plans Mukesh Ambani, India's richest man, said telecom was the first of his big bet, and he will now use his resources to solve problems in three other difficult areas -- agriculture, education and healthcare. Speaking at the HT Leadership Summit, Ambani said his primary motivation...
Zydus Cadila gets USFDA nod to launch generic version of billion-dollar drug Cialis eventually The United States Food and Drug Administration has given Zydus Cadila approval to launch a generic version of the billion-dollar erectile dysfunction drug Cialis when patents expire. The patents are expected to expire in September next year. Cialis and Viagra are the most ...
Glenmark Pharma to launch birth control pill in USA Glenmark Pharmaceuticals said it got the approval of the United States Food & Drug Administration to launch a generic version of birth control pill Loestrin from Allergan Pharmaceuticals International. The drug had annual sales of approximately $116.8 million. The drug Nor...
Strides Shasun gets USFDA nod to launch nausea drug Strides Shasun Limited said it received approval from the United States Food & Drug Administration (USFDA) to launch a generic version of Diamox Tablets. The primary use of the Acetazolamide is to reduce nausea and dizziness associated with altitude sickness, but the drug is ...
After Lupin, Ajantha Pharma too launches generic ADHD drug in US A month after Lupin got it, Ajanta Pharma too said it got the approval to launch a generic version of Concordia Pharmaceuticals Inc.’s ADHD drug Kapvay. Lupin had got the nod in October, and said the drug had sales of around $66 mln in the US. Ajantha Pharma also said it ha...
Cipla gets US approval for cancer drug, Glenmark for oral contraceptive Two Indian pharmaceutical companies, Cipla and Glenmark, said they received approval from the US Food and Drug Administration for new drugs. While Cipla got the nod for a drug used to treat a type of blood cancer, Glenmark was approved to sell an oral contraceptive. Cipla...
Zydus gets nod for anti-inflammation drug in the US Pharma major Zydus Cadila said it received final approval from the USFDA to market an anti-inflammatory injection Ethacrynate Sodium in the US. The drug is used to decrease the Swelling (edema) caused by various disease conditions such as liver disease, kidney disease, conges...
Lupin gets USFDA warning on Goa, Indore plans, to affect new approvals Pharma major Lupin said it a warning letter from the US Food and Drug Administration for its formulations manufacturing facilities in Goa and Indore on Monday. "We are deeply disappointed to hove received this outcome. While there will be no disruption of existing product sup...
Lupin gets USFDA approval for generic ADHD drug Pharma Major Lupin said it received final approval from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals Inc.’s ADHD drug Kapvay. It had annual sales of approximately USD 66 million in the US. Clonidine Hydrochlo...
USFDA returns Mylan-Biocon’s drug application for more data The U.S. Food and Drug Administration has sought more data before approving a chemotherapy compound submitted by Mylan and jointly developed by Biocon. The agency issued a 'complete response letter'. Such letters are issued when an FDA review an FDA review finds that an appli...
Lupin gets FDA nod to launch heart drug in the US Pharma manufacturer Lupin said it received approval to launch the generic version of US World Meds' Corgard heart drug. Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg Tablets had annual sales of approximately USD 109.8 million in the US, the Indian drugmaker said. Lupin's N...
Zydus Cadila gets USFDA nod for overactive bladder drug Zydus Cadila said it received the final approval to launch overactive bladder drug Fesoterodine Fumarate in the US. The sales of Fesoterodine Fumarate Extended-Release Tablets are estimated at $195.5 million. It will be manufactured at the group’s formulations manufacturin...
NATCO Pharma to sell multiple sclerosis drug in USA via Mylan NATCO Pharma Limited said it the US Food and Drug Administration approved the generic drug application filed by its marketing partner Mylan for injections used in the treatment of multiple sclerosis, a chronic inflammatory disease of the central nervous system. The drug, Glat...
AU Small Finance Bank to distribute Aditya Birla Health insurance AU Small Finance Bank has tied up with Aditya Birla Health Insurance to to distribute the latter's health insurance products. The bank will act as a corporate agent, it said. "This tie up shall be mutually beneficial for ABHICL & AU SMALL FINANCE BANK in terms of business,...